Literature DB >> 32487605

New Pancreatic Cancer Biomarkers eIF1, eIF2D, eIF3C and eIF6 Play a Major Role in Translational Control in Ductal Adenocarcinoma.

Nicole Golob-Schwarzl1,2, Philip Puchas1, Margit Gogg-Kamerer1, Wilko Weichert3, Benjamin Göppert4, Johannes Haybaeck5,6.   

Abstract

BACKGROUND/AIM: Pancreatic cancer is one of the deadliest forms of cancer and ranks among the leading causes of cancer-related death worldwide. The most common histological type is ductal adenocarcinoma (PDAC), accounting for approximately 95% of cases. Deregulation of protein synthesis has been found to be closely related to cancer. The rate-limiting step of translation is initiation, which is regulated by a broad range of eukaryotic translation initiation factors (eIFs). PATIENTS AND METHODS: Human PDAC samples were biochemically analyzed for the expression of various eIF subunits on the protein level (immunohistochemistry, immunoblot analyses) in 174 cases of PDAC in comparison with non-neoplastic pancreatic tissue (n=10).
RESULTS: Our investigation revealed a significant down-regulation of four specific eIF subunits, namely eIF1, eIF2D, eIF3C and eIF6. Concomitantly, the protein (immunoblot) levels of eIF1, eIF2D, eIF3C and eIF6 were reduced in PDAC samples as compared with non-neoplastic pancreatic tissue.
CONCLUSION: Members of the eIF family are of relevance in pancreatic tumor biology and may play a major role in translational control in PDAC. Consequently, they might be useful as potential new biomarkers and therapeutic targets in PDAC. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  PI3K/AKT/mTOR pathway; Pancreatic cancer; biomarker; eukaryotic translation initiation factors

Year:  2020        PMID: 32487605     DOI: 10.21873/anticanres.14292

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  An Integrated Data Analysis of mRNA, miRNA and Signaling Pathways in Pancreatic Cancer.

Authors:  Ehsan Sohrabi; Ehsan Rezaie; Mohammad Heiat; Yousef Sefidi-Heris
Journal:  Biochem Genet       Date:  2021-04-03       Impact factor: 1.890

2.  Diagnostic and prognostic utility of eIF6 in glioblastoma: a study based on TCGA and CGGA databases.

Authors:  Jian Liang; Fengyu Liu; Yaoqiang Yang; Xing Li; Guangmou Cai; Jianxuan Cao; Bo Zhang
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

3.  eIF6 is potential diagnostic and prognostic biomarker that associated with 18F-FDG PET/CT features and immune signatures in esophageal carcinoma.

Authors:  Yan Gao; Lingling Yuan; Jing Zeng; Fuyan Li; Xiaohui Li; Fan Tan; Xusheng Liu; Huabing Wan; Xueyan Kui; Xiaoyu Liu; Changbin Ke; Zhijun Pei
Journal:  J Transl Med       Date:  2022-07-06       Impact factor: 8.440

Review 4.  A Review: PI3K/AKT/mTOR Signaling Pathway and Its Regulated Eukaryotic Translation Initiation Factors May Be a Potential Therapeutic Target in Esophageal Squamous Cell Carcinoma.

Authors:  Ran Huang; Qiong Dai; Ruixue Yang; Yi Duan; Qi Zhao; Johannes Haybaeck; Zhihui Yang
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

5.  eIF6 promotes the malignant progression of human hepatocellular carcinoma via the mTOR signaling pathway.

Authors:  Liping Sun; Shuguang Liu; Xiaopai Wang; Xuefeng Zheng; Ya Chen; Hong Shen
Journal:  J Transl Med       Date:  2021-05-20       Impact factor: 5.531

6.  A Cancer Cell Cluster Marked by LincRNA MEG3 Leads Pancreatic Ductal Adenocarcinoma Metastasis.

Authors:  Hong Pan; Huanrong Diao; Wen Zhong; Taifang Wang; Ping Wen; Chunli Wu
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

7.  ID1 marks the tumorigenesis of pancreatic ductal adenocarcinoma in mouse and human.

Authors:  Yuanxin Tang; Sheng Zhang; Jiazi Li; Chunli Wu; Qing Fan
Journal:  Sci Rep       Date:  2022-08-08       Impact factor: 4.996

8.  Expression, oncological and immunological characterizations of BZW1/2 in pancreatic adenocarcinoma.

Authors:  Jiachen Ge; Senmao Mu; Erwei Xiao; Guangjin Tian; Lianyuan Tao; Deyu Li
Journal:  Front Genet       Date:  2022-10-04       Impact factor: 4.772

Review 9.  Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma.

Authors:  Geeta G Sharma; Yasuyuki Okada; Daniel Von Hoff; Ajay Goel
Journal:  Semin Cancer Biol       Date:  2020-10-10       Impact factor: 17.012

10.  Apatinib inhibits pancreatic cancer growth, migration and invasion through the PI3K/AKT and ERK1/2/MAPK pathways.

Authors:  Enxiao Li; Yangwei Fan; Yuan Hu; Jiayu Jing; Yu Shi; Pengchuang Zhang; Danfeng Dong; Yinying Wu; Xuyuan Dong
Journal:  Transl Cancer Res       Date:  2021-07       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.